Research on prostate cancer risk factors published by scientists at Helsinki University, Department of Urology

Research findings, "Ten-year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy," are discussed in a new report. According to a study from Helsinki, Finland, "The aim of the study was to evaluate overall and prostate cancer (PCa) specific survival with special attention to cardiovascular (CV) mortality in patients primarily treated by parenteral polyestradiol phosphate (PEP) 240 mg/month or with orchiectomy (OE), taking into account the effect of pretreatment diseases and medication, and later PCa therapies. The present Finnprostate 6 study (10-year follow-up) consisted of 244 patients...

Want to see the full article?

• Purchase this article for only $3.00